EyePoint, Inc. (EYPT) stock
Close on Nov 12, 2026Market cap $27.54MP/E –Yield –
EyePoint, Inc. saw revenue fall 93.9% to $2.58M over the twelve months to Sep 30, 2026. Free cash flow was -$299.15M. At the latest close the market valued the company at $27.54M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $27.54M
- P/E ratio
- –
- Price to sales
- 10.68
- Price to book
- 0.25
- Dividend yield
- –
- Free cash flow yield
- -1086.05%
Fundamentals
- Revenue
- $2.58M
- Net income
- -$342.52M
- EPS, diluted
- -$3.17
- Free cash flow
- -$299.15M
- Book value per share
- $1215.82
- Diluted shares
- 0M
Trading
- Next earnings
- Mar 3, 2027 (estimated, before the open)
- Previous close
- $0.36
- Open
- $0.35
- Day's range
- $0.31 – $0.36
- Volume
- 5,967,722
- Average volume (20 days)
- 19,023,201
- Index membership
- Russell 2000 (since Jun 2021), Russell 3000 (since Aug 2021)
- Beta (5 years)
- 1.73
- 52-week range
- $0.31 – $19.11
- RSI (14 days)
- 18.4
- Volatility (1 year)
- 132.6%
- Relative volume
- 0.83×
- WACC
- 13.5%
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2010, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | EYPT | S&P 500 | Difference | EYPT per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -90.4% | -2.7% | −87.7 pts | ||
| 3 months | -97.6% | -1.7% | −95.9 pts | ||
| Year to date | -98.3% | +11.9% | −110.1 pts | ||
| 1 year | -97.3% | +12.0% | −109.3 pts | ||
| 3 years | -95.0% | +78.2% | −173.2 pts | -63.2% | +21.2% |
| 5 years | -97.7% | +73.2% | −171.0 pts | -53.1% | +11.6% |
| 10 years | -98.3% | +309.6% | −408.0 pts | -33.6% | +15.1% |
Fifteen years at a glance
Fiscal years 2010 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases EyePoint filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- News
- News
- News
- News
About EyePoint
Laboratory Analytical Instruments
EyePoint, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics to treat serious retinal diseases. The company's pipeline utilizes its proprietary bioerodible Durasert E technology designed for sustained intraocular drug delivery. Its primary product candidate is DURAVYU, an investigational sustained-delivery therapy that pairs the tyrosine kinase inhibitor vorolanib with Durasert E to treat vascular endothelial growth factor-mediated retinal conditions, specifically wet age-related macular degeneration and diabetic macular edema. The company also advances EYP-2301 and maintains commercial arrangements regarding YUTIQ and DEXYCU for ophthalmic care.
Company profile, executives and historyEyePoint stock: common questions
What is EyePoint's stock price?
EYPT closed at $0.32 on Nov 12, 2026, down 10.40% on the day. Over the past 52 weeks it traded between $0.31 and $19.11.
What is EyePoint's market cap?
EyePoint was worth $27.54M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is EYPT's P/E ratio?
EyePoint lost money over fiscal 2025 (diluted EPS -$3.17), so it has no meaningful P/E ratio.
How much revenue does EyePoint make?
EyePoint reported revenue of $2.58M for the twelve months to Sep 30, 2026, down 93.9% from a year earlier.
Does EyePoint pay a dividend?
No. EyePoint has not paid a cash dividend over the last twelve months.
When does EyePoint report earnings next?
EyePoint is expected to report Q4 FY2026 results on Mar 3, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has EYPT stock performed over the past year?
Including dividends, EYPT returned -97.3% over the past year, against +12.0% for the S&P 500.
How many EYPT shares are sold short?
11M shares were sold short at the latest FINRA report, 12.91% of the float, or 1.0 days of average trading volume.
Who are EyePoint's competitors?
Companies most similar to EyePoint by business, industry and size include SCND, QSI, OTLK, RNXT, ASTC.
See a number that looks wrong?